Digestive Diseases and Sciences

, Volume 55, Issue 4, pp 1085–1089 | Cite as

Polycystic Ovary Syndrome Is Associated with an Increased Prevalence of Irritable Bowel Syndrome

  • Ruchi Mathur
  • Ara Ko
  • Laura J. Hwang
  • Kimberly Low
  • Ricardo Azziz
  • Mark PimentelEmail author
Original Article



Polycystic ovary syndrome (PCOS) affects 5–10% of reproductive-aged women. Irritable bowel syndrome (IBS) is a chronic intestinal disorder that affects up to 20% of adults, more often women. We evaluate if there is a relationship between these common conditions.


Polycystic ovary syndrome and control subjects were prospectively recruited. A questionnaire was given to determine their gastrointestinal symptoms. Body mass index (BMI) and percent body fat were also calculated.


About 65 female subjects completed the study. Among the 36 PCOS patients, 15 subjects (42%) had IBS, compared to 3 subjects (10%) among controls (p < 0.01). Control subjects were leaner (BMI: 27.5 ± 1.1 vs. 31.4 ± 1.2 kg/m2, p < 0.05) than PCOS patients. Among women with PCOS, those with IBS had a higher BMI (32.9 ± 2.0 kg/m2) compared to those with PCOS but no IBS (30.3 ± 1.6 kg/m2) and controls (27.5 ± 1.1 kg/m2; p < 0.05). This difference was true even after correcting for BMI and age (p < 0.01).


Women with PCOS have a higher prevalence of IBS compared to healthy controls. When IBS is present with PCOS, a higher BMI and percent body fat is seen compared to PCOS alone.


Polycystic ovary syndrome Irritable bowel syndrome 


  1. 1.
    Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1,000 consecutive patients. J Clin Endocrinol Metab. 2004;89(2):453–462.CrossRefPubMedGoogle Scholar
  2. 2.
    Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed). 1986;293(6543):355–359.CrossRefGoogle Scholar
  3. 3.
    Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006;91(3):781–785.CrossRefPubMedGoogle Scholar
  4. 4.
    Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223–1236.CrossRefPubMedGoogle Scholar
  5. 5.
    Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(1):162–168.CrossRefPubMedGoogle Scholar
  6. 6.
    Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1992;36(1):105–111.CrossRefGoogle Scholar
  7. 7.
    Orio F, Vuolo L, Palomba S, Lombardi G, Colao A. Metabolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecol. 2008;60(1):39–51.PubMedGoogle Scholar
  8. 8.
    Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86:2453–2455.CrossRefPubMedGoogle Scholar
  9. 9.
    Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab. 1987;65:499–507.CrossRefPubMedGoogle Scholar
  10. 10.
    Bommelaer G, Poynard T, Le Pen C, et al. Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroentérologie clinique et biologique. 2004;28:554–561.CrossRefPubMedGoogle Scholar
  11. 11.
    Wilson S, Roberts L, Roalfe A, Bridge P, Singh S. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract. 2004;54:495–502.PubMedGoogle Scholar
  12. 12.
    Gwee KA, Wee S, Wong ML, Png DJ. The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community. Am J Gastroenterol. 2004;99:924–931.CrossRefPubMedGoogle Scholar
  13. 13.
    El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord. 2003;3(Suppl 2):S3–11.Google Scholar
  14. 14.
    Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Ailment Pharmacol Ther. 2003;17:643–650.CrossRefGoogle Scholar
  15. 15.
    Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995;109:671–680.CrossRefPubMedGoogle Scholar
  16. 16.
    Drossman DA, Zhiming L, Andruzzi E, et al. US householders survey of functional gastrointestinal disorders. Dig Dis Sci. 1993;38:1569–1580.CrossRefPubMedGoogle Scholar
  17. 17.
    Saito YA, Schoenfeld P, Locke GRI. The epidemiology of irritable bowel syndrome in North America: a systemic review. Am J Gastroenterol. 2002;97:1910–1915.PubMedGoogle Scholar
  18. 18.
    Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.CrossRefPubMedGoogle Scholar
  19. 19.
    Lee OY, Mayer EA, Schmulson M, Chang L, Naliboff B. Gender-related differences in IBS symptoms. Am J Gastroenterol. 2001;96:2184–2193.CrossRefPubMedGoogle Scholar
  20. 20.
    Talley NJ, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut. 1998;42:690–695.PubMedCrossRefGoogle Scholar
  21. 21.
    Corney RH, Stanton R. Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. J Psychosom Res. 1990;34:483–491.CrossRefPubMedGoogle Scholar
  22. 22.
    Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell; 1992:377–384.Google Scholar
  23. 23.
    Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412–419.PubMedGoogle Scholar
  24. 24.
    Drossman DA, Richter JE, Talley NJ, et al., eds. Functional gastrointestinal disorders: diagnosis, pathophysiology, and treatment: a multinational consensus. Boston: Little Brown; 1994.Google Scholar
  25. 25.
    Hungin AP, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther. 2005;21(11):1365–1375.CrossRefPubMedGoogle Scholar
  26. 26.
    Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology. 1997;112:2120–2137.CrossRefPubMedGoogle Scholar
  27. 27.
    Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Ailment Pharmacol Ther. 1999;13:1149–1159.CrossRefGoogle Scholar
  28. 28.
    Mueller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Ailment Pharmacol Ther. 2000;15:1655–1666.CrossRefGoogle Scholar
  29. 29.
    Sperber AD, Atzmon Y, Neumann L, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol. 1999;94:3541–3546.CrossRefPubMedGoogle Scholar
  30. 30.
    Giamberardino M. Sex-related and hormonal modulation of visceral pain. In: Fillingim R, ed. Sex gender and pain, vol. 17. Seattle: IASP; 2000.Google Scholar
  31. 31.
    Messing EM and Stamey TA. Intersititial cystitis: early diagnosis, pathology, and treatment. Urology. 1978;12:381–392.CrossRefGoogle Scholar
  32. 32.
    Koziol JA, Clark DC, Gittes RF, et al. The natural history of interstitial cystitis: a survey of 374 patients. J Urol. 1993;149:465–469.PubMedGoogle Scholar
  33. 33.
    Hand JR. Interstitial cystitis: report of 223 cases (204 women and 19 men). J Urol. 1949;61:291–310.PubMedGoogle Scholar
  34. 34.
    Simon LJ, Landis JR, Erickson DR, et al. The interstitial cystitis data base study: concepts and preliminary baseline descriptive statistics. Urology. 1997;49:64–75.CrossRefPubMedGoogle Scholar
  35. 35.
    Wolfe F, Ross K, Anderson J. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19–28.CrossRefPubMedGoogle Scholar
  36. 36.
    Heitkemper MM, Jarrett M. Patterns of gastrointestinal and somatic symptoms across the menstrual cycle. Gastroenterology. 1992;102:505–513.PubMedGoogle Scholar
  37. 37.
    Whitehead WE, Cheskin LJ, Heller BR, et al. Evidence for exacerbation of irritable bowel syndrome during menses. Gastroenterology. 1990;98:1485–1489.PubMedGoogle Scholar
  38. 38.
    Heitkemper MM, Cain KC, Jarrett ME, Burr RL, Hertig V, Bond EF. Symptoms across the menstrual cycle in women with irritable bowel syndrome. Am J Gastroenterol. 2003;98(2):420–430.CrossRefPubMedGoogle Scholar
  39. 39.
    Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril. 2002;77(6):1095–1105.CrossRefPubMedGoogle Scholar
  40. 40.
    Talley NJ, Howell S, Poulton R. Obesity and chronic gastrointestinal tract symptoms in young adults: a birth cohort study. Am J Gastroenterol. 2004;99:1807–1814.CrossRefPubMedGoogle Scholar
  41. 41.
    Delgado-Aros S, Locke GR 3rd, Camilleri M, et al. Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J of Gastroenterol. 2004;99(9):1801–1806.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Ruchi Mathur
    • 1
    • 2
    • 3
  • Ara Ko
    • 1
  • Laura J. Hwang
    • 4
  • Kimberly Low
    • 4
  • Ricardo Azziz
    • 1
    • 3
  • Mark Pimentel
    • 4
    • 5
    Email author
  1. 1.Department of Obstetrics/GynecologyCedars-Sinai Medical CenterLos AngelesUSA
  2. 2.Department of MedicineCedars-Sinai Medical CenterLos AngelesUSA
  3. 3.Department of Obstetrics/GynecologyThe David Geffen School of Medicine at UCLALos AngelesUSA
  4. 4.GI Motility ProgramCedars-Sinai Medical CenterLos AngelesUSA
  5. 5.Division of Gastroenterology, Department of MedicineCedars-Sinai Medical CenterLos AngelesUSA

Personalised recommendations